Merus N.V., an oncology company, has announced the publication of research detailing the mechanism of action of their bispecific antibody, petosemtamab. The antibody targets Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), with findings published in the scientific journal "Cancers." Petosemtamab has shown significant clinical activity in treating recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC), with ongoing Phase 3 trials for both first-line and second/third-line treatments. Additionally, a Phase 2 trial is underway to evaluate petosemtamab in combination with standard chemotherapy for metastatic colon cancer (mCRC). The antibody works through three mechanisms: blocking EGFR ligands, causing EGFR receptor degradation in LGR5+ cells, and activating the immune system via antibody-dependent cellular phagocytosis and cytotoxicity. Initial clinical data for its application in mCRC is expected in the second half of 2025.